Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions

a technology of immunogenic compositions and mycoplasma hyopneumoniae, which is applied in the direction of antibody medical ingredients, drug compositions, immunological disorders, etc., can solve the problems of low amount of orf2 recovered from cells, high extraction procedures, and high cost and time consumption, so as to reduce the severity or incidence of clinical signs. , the effect of reducing the severity

Inactive Publication Date: 2009-12-24
BOEHRINGER LNGELHEIM VETMEDICA GMBH
View PDF99 Cites 57 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0048]Injection timing is flexible. Compositions as described herein can be used as early as three weeks of age through the time when pigs leave the nursery with the objective of vaccinating at least 2 weeks prior to exposure to Mycoplasma hyopneumoniae. The composition according to the invention may be applied in any conventional manner including intradermally, intratracheally, or intravaginally. The composition preferably may be applied intramuscularly or intranasally. In an animal body, it can prove advantageous to apply the pharmaceutical compositions as described above via an intravenous injection or by direct injection into target tissues. For systemic application, the intravenous, intravascular, intramuscular, intranasal, intra-arterial, intraperitoneal, oral, or intrathecal routes are preferred. A more local

Problems solved by technology

However, these procedures have a disadvantage in that the extraction procedures are both costly and time-consuming.
Additionally, the amount of ORF2 recovered from the cells is not very high; conseq

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0061]The study design was set up to evaluate the combination efficacy of PCV2-M. hyo at full and 2×½ dose, at two different inclusion levels of M. hyo for the combination product and also to demonstrate any interference of the combination product compared to the monovalent M. hyo.

Materials and Methods:

[0062]Pigs were divided into 6 groups. All of the challenge groups (Groups 1-5) had around 19 pigs in each group. The control group containing pigs that were not given treatment and were not challenged (Group 6) had 5 pigs in the group. All pigs were necropsied on Day 61 of the study. The Schedule of the Investigation is shown below in Table 1

TABLE 1Study Day(approximately)Study EventBefore Day 0ID pigs; Health examination(D0)Before D0Randomize pigs to one of five groupsD-2All pigs: Collect blood samples; Clinical AssessmentsD0All pigs: Clinical AssessmentsD0Administer Investigational Veterinary Product 1 (IVP1) to Group1; Administer Investigational Veterinary Product 2 (IVP2) toGroup...

example 2

[0073]This study design was set up to determine the duration of immunity of the combination vaccine.

Materials and Methods:

[0074]Pigs were divided into 6 groups. All of the challenge groups (Groups 1-5) had around 19 pigs in each group. The control group containing pigs that were not given treatment and were not challenged (Group 6) had 5 pigs in the group. The Schedule of the Investigation is shown below in Table 3.

TABLE 3Challenge withGroupNumberTreatment on D0Treatment on D12On D331≧191.0 mL of IVP-1 (50 mLN / AYesof M. hyo Bacterin) IM inthe neck region2≧192.0 mL of IVP-2 (100N / AYesmL: 50 mL of M. hyoBacterin and 50 mL ofPCV2 vaccine) IM in theneck region3≧191.0 mL of IVP-3 (1001.0 mL of IVP-3YesmL: 50 mL of M. hyo(100 mL: 50 mL of M.Bacterin and 50 mL ofhyo Bacterin and 50 mLPCV2 vaccine) IM in theof PCV2 vaccine) IM inneck regionthe neck region4≧192.0 mL of IVP-3 (100N / AYesmL: 50 mL of M. hyoBacterin and 50 mL ofPCV2 vaccine) IM in theneck region5≧192.0 mL of CP (50 mL1.0 mL of C...

example 3

[0079]This investigation was carried out to determine the amount of interference observed when mixing an antigen of M. hyo with an antigen of PCV2. The study demonstrated that the M. hyo component of the vaccine was still effective in the presence of PCV2.

Materials and Methods

[0080]Pigs were 3 weeks±5 days of age at vaccination. Group 1 was vaccinated with a single 2 ml dose of M. hyo antigen in the form of a bacterin. Group 2 was vaccinated with a single 2 ml dose of equal amounts of M. hyo antigen and PCV2 antigen. Group 3 was a challenge control group and Group 4 was a strict control group. Groups 1-3 were subsequently challenged on D33 with a virulent M. hyo isolate. All animals in the study were necropsied at D61.

Results and Discussion

[0081]Upon necropsy, lungs were scored. Group 1, vaccinated with M. hyo antigen, only had average gross lung pathology of 5.5% (P>0.001). Group 2, vaccinated with M. hyo antigen and PCV2 antigen, had average gross lung pathology of 3.9% (P>0.001)....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Timeaaaaaaaaaa
Login to view more

Abstract

Multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of M. hyo infection, preferably M. hyo bacterin, or an immunogenic composition comprising M. hyo bacterin, and at least one immunogenic active component of another disease-causing organism in swine, preferably PCV2 wherein the preferred PCV2 antigen for such a multivalent vaccine is PCV2 ORF 2 protein.

Description

RELATED APPLICATIONS[0001]This application claims the priority benefit of U.S. provisional application Ser. No. 61 / 023,086, filed on Jan. 23, 2008 and U.S. provisional Ser. No. 61 / 025,293, filed on Jan. 31, 2008. The teachings and content of both of these applications are hereby incorporated by reference herein.BACKGROUND OF THE INVENTION[0002]1. Field of the Invention[0003]In one aspect of the present invention, an immunogenic composition effective for inducing an immune response against infection by Mycoplasma hyopneumoniae (M. hyo) is provided. More particularly, the present invention is concerned with an immunogenic composition effective for inducing, eliciting, or providing an immune response that protects an animal receiving such a composition and reduces the incidence of, or lessens the severity of, the clinical symptoms associated with M. hyo infection. Still more particularly, the present invention is concerned with an immunogenic composition that includes therein cell-base...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/295
CPCA61K39/0241A61K39/12C12N2750/10034A61K2039/552A61K2039/55555A61K2039/525A61K2039/70A61P11/00A61P31/00A61P37/00A61K39/0208A61K39/39A61K2039/545C12N7/00C12N2750/10071
Inventor ROOF, MICHAELEICHMEYER, MARC
Owner BOEHRINGER LNGELHEIM VETMEDICA GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap